Core Viewpoint - Chongqing Mountain Outside Blood Purification Technology Co., Ltd. (referred to as "Mountain Outside") expects significant growth in net profit for the year 2025, with projections indicating an increase of 98% to 125% year-on-year [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 140 million to 159 million yuan for 2025, representing a substantial year-on-year growth [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 134 million to 154 million yuan, reflecting a year-on-year increase of 135% to 170% [1] Group 2: Business Operations - Mountain Outside specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain dialysis medical services [1] - The company has developed key technologies for blood purification equipment, including Continuous Renal Replacement Therapy (CRRT) devices, dialysis machines, and blood perfusion machines, along with various consumables [1] - The company's products are widely used in treating various conditions such as acute and chronic renal failure, uremia, multiple organ failure, and poisoning [1] Group 3: Market Position and Growth - As a leading domestic blood purification equipment manufacturer, Mountain Outside has seen a continuous increase in market share due to its technological advantages and strong brand effect [2] - The sales revenue from self-produced blood purification consumables has also significantly increased, contributing to overall revenue growth [2] - With the increase in production and sales volume, the fixed costs of self-produced consumables have decreased, leading to improved gross margins and enhanced overall profitability [2]

本土血液净化设备龙头企业山外山(688410)上市2年多来，营业收入和净利润一再出现大幅波动，公司 2024年营收同比下滑17.80%，净利润大降63.55%。5月8日，山外山两股东抛出减持计划，计划减持合 计不超过公司总股本4%的股份。 年报业绩下滑两股东拟减持不超过4% 山外山是重庆首家在科创板上市的企业，2022年12月上市，发行股票数量为3619万股，发行价格为 32.30元/股。上市2年多来，山外山业绩经历了不小的波动。 2023年，山外山实现营业收入6.9亿元，同比增长80.65%；归属净利润1.95亿元，同比增长228.34%。不 过，2024年公司业绩大幅回调，全年实现营收5.67亿元，同比下降17.80%，归属净利润为0.71亿元，大 降63.55% 年报披露后，山外山5月8日发布公告称，股东湖南湘江力远投资管理有限公司-湖南湘江大健康创业投 资合伙企业(有限合伙)、湖南湘江力远投资管理有限公司-湖南湘江力远健鲲创业投资合伙企业(有限合 伙)因自身资金需求，拟通过集中竞价交易或大宗交易的方式减持其所持有的公司股份合计不超过 1285.26万股，本次减持比例合计不超过公司总股本4%，自本减持计 ...